Filter Results

Tocilizumab for SARS-CoV-2

Tocilizumab, a monoclonal antibody against interleukin-6 (IL-6), has emerged as an alternative treatment for COVID-19 patients with a risk of cytokine storms recently. In recent studies, clinicians have discussed the treatment response of Tocilizumab therapy in COVID-19 infected patients. The demographic, treatment, laboratory parameters of C-reactive protein (CRP) and IL-6 before and after Tocilizumab therapy and clinical outcome in COVID-19 patients were retrospectively assessed.

Tocilizumab appears to be an effective treatment option in COVID-19 patients with a risk of cytokine storms. And for critically ill patients with elevated IL-6, the repeated dose of the Tocilizumab is recommended.

Genentech, maker of another IL-6 inhibitor, Tocilizumab (Actemra), is working with the FDA to initiate a randomized, double-blind, placebo-controlled phase III clinical trial in collaboration with BARDA to evaluate the safety and efficacy of Tocilizumab plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia compared to placebo plus standard of care. The primary and secondary endpoints of the study include clinical status, mortality, mechanical ventilation, and ICU variables.

An open label, non-controlled, non–peer reviewed study was conducted in China in 21 patients with severe respiratory symptoms related to COVID-19. All had a confirmatory diagnosis of SARS-CoV-2 infection

KRISHGEN BIOSYSTEMS offers a CE marked kit for measurement of Tocilizumab (ACTEMRA) ELISA. The ELISA estimates the levels of Tocilizumab in human serum and plasma.

Cat No Product Particulars Pack Size
KBI1022 KRIBIOLISA™ Tocilizumab (ACTEMRA) ELISA ELISA 96 wells


Tocilizumab treatment in COVID-19: A single center experience.

J Med Virol. 2020 Apr 6. doi: 10.1002/jmv.25801.

Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J.

Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

FDA Approves Phase III Clinical Trial of Tocilizumab for COVID-19 Pneumonia

CancerNetwork - home of the journal ONCOLOGY

by Hannah Slater, March 26, 2020





    Join KRISHGEN as a verified distributor to get access to over 1 million sku’s, including reagents, biochemicals and assays. Your one stop vendor for life sciences.

    Subscribe Newsletter


    Krishgen Support